Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 24%
Buy 59%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie has demonstrated a robust financial outlook, with management revising global sales guidance for its neuroscience segment to approximately $10.7 billion for 2025, reflecting strong performance across several key products including Vyalev, Vraylar, and Botox Therapeutic. Additionally, the upward revisions in mid-term growth rate estimates for Skyrizi and Rinvoq indicate a positive trajectory in AbbVie's immunology franchise, reinforcing confidence in its future revenue streams. Furthermore, significant global sales growth observed in 3Q25 across several products, combined with the strategic acquisitions of Cerevel and ImmunoGen, enhances AbbVie's potential to sustain and drive its market position in both neurology and oncology sectors.

Bears say

The financial outlook for AbbVie appears negative due to lowered mid-term sales estimates for its aesthetics franchise, particularly concerning Botox and fillers, which have experienced ongoing pressure. Risks include potential shortcomings in commercial execution for significant assets like Skyrizi and Rinvoq, along with clinical setbacks that could hinder growth opportunities for marketed products. Additionally, looming exclusivity loss for Vraylar in 2030 and ongoing macroeconomic pressures that could affect discretionary spending further compound concerns regarding AbbVie's revenue trajectory.

AbbVie (ABBV) has been analyzed by 17 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 59% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 17 analysts, AbbVie (ABBV) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $255.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $255.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.